Nonetheless, METN375S-tGFP tumors were more sensitive, particularly to trastuzumab where tumor regression was attained at tolerable doses with significant dephosphorylation of MET in addition to the ablation of HER2 activity (Fig. 6k, l; Supplementary Fig. 8H, I), likely due to the interference with heterodimerization between HER2 and METN375S. Here, ERBB2 is linked to neoplasm.